疫苗在慢性阻塞性肺疾病患者中的作用

珺 周(承德医学院附属医院呼吸与危重症医学科，中国)
桂芬 庞(承德医学院附属医院呼吸与危重症医学科，中国)

摘要

慢性阻塞性肺疾病是一种常见的慢性呼吸系统疾病，其发病率仍逐年增加。慢性阻塞性肺疾病急性加重是在慢阻肺基础上出现需要改变原有治疗的呼吸道症状的急性恶化，是慢阻肺患者住院和死亡最常见的原因。感染是导致慢阻肺疾病急性加重的主要原因，在该病的发生发展过程中发挥重要作用。疫苗接种是一种可以有效地降低相关病原体感染导致的慢阻肺急性加重的方法，然而，目前疫苗的覆盖率和认知度很低，医务人员及卫生机构需要更有效地向该类患者传达疫苗接种的益处。论文综述疫苗接种对慢阻肺患者的影响。

关键词

疫苗；疫苗接种；慢性阻塞性肺疾病

参考

Global Initiative for Chronic Obstructive Lung Disease (GOLD).Global strategy for prevention,diagnosis and management of COPD:2023 Report[EB/OL].[2022-11-14]. https://goldcopd.org/2023-gold-report-2/.

慢性阻塞性肺疾病急性加重诊治专家组.慢性阻塞性肺疾病急性加重诊治中国专家共识(2023年修订版)[J].国际呼吸杂志,2023,43(2):132-149.

Zhang Q, Liang T, Nandakumar KS, et al. Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors[J]. Expert Opin Pharmacother, 2021,22(6):715-728.

Creytens S, Pascha MN, Ballegeer M, et al. Influenza neuraminidase characteristics and potential as a vaccine target[J]. Front Immunol, 2021,12:786617.

国家免疫规划技术工作组流感疫苗工作组.中国流感疫苗预防接种技术指南(2022—2023)[J].中华流行病学杂志,2022,43(10):1515-1544.

Bao W, Li Y, Wang T, et al. Effects of influenza vaccination on clinical outcomes of chronic obstructive pulmonary disease:a systematic review and meta-analysis[J]. Ageing Res Rev, 2021,68:101337.

Mulpuru S, Li L, Ye L, et al. Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD[J]. Chest, 2019,155(1):69-78.

Mallia P, Johnston SL. Influenza infection and COPD[J]. Int J Chron Obstruct Pulmon Dis, 2007,2(1):55-64.

Fan J, Cong S, Wang N, et al. Influenza vaccination rate and its association with chronic diseases in China:results of a national cross-sectional study[J]. Vaccine, 2020,38(11):2503-2511.

Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases[J]. Int J Chron Obstruct Pulmon Dis, 2017,12:3457-3468.

Søgaard M, Madsen M, Løkke A, et al. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia[J]. Int J Chron Obstruct Pulmon Dis, 2016,11:455-465.

王雪,韦会红,黄婕,等.流感疫苗和肺炎疫苗预防COPD急性加重的作用[J].国际呼吸杂志,2017,37(21):1646-1649.

Walters JA, Tang JN, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2017,1(1):CD001390.

随海田,郭昱,杨中楠,等.慢性阻塞性肺疾病患者流感疫苗和23价肺炎链球菌多糖疫苗接种研究进展[J].中华流行病学杂志,2022,43(9):1508-1512.

徐娜,罗坤,李春玉.23价肺炎链球菌多糖疫苗对慢性阻塞性肺疾病影响的荟萃分析[J].职业与健康,2020,36(1):114-118.

Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD[J]. Thorax, 2006,61(3):189-195.

Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal

conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years:updated recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019,68(46):1069-1075.

Ignatova GL, Avdeev SN, Antonov VN. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study[J]. Sci Rep, 2021,11(1):15948.

胡昱,汪颖,梁辉,等.成人接种13价肺炎链球菌多糖结合蛋白疫苗与23价肺炎链球菌多糖疫苗的免疫原性及安全性差异的Meta分析[J].国际流行病学传染病学杂志,2020,47(4):335-340.

Mohr A, Plentz A, Sieroslawski A, et al. Use of pneumococcal and influenza vaccine in patients with COPD,asthma bronchiale and interstitial lung diseases in south east Germany[J]. Respir Med, 2020,174:106207.

Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the united states:recommendations of the advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep, 2018,67(2):1-44.

曾利娴.两种百白破联合疫苗接种副反应的研究进展[J].国际医药卫生导报,2010,16(1):127-129.

Havers FP, Moro PL, Hunter P, et al. Use of tetanus toxoid,reduced diphtheria toxoid, and acellular pertussis vaccines:updated recommendations of the Advisory Committee on Immunization Practices - United States, 2019[J]. MMWR Morb Mortal Wkly Rep, 2020,69(3):77-83.

Szwejser-Zawislak E, Wilk MM, Piszczek P, et al. Evaluation of whole-cell and acellular pertussis vaccines in the context of long-term herd immunity[J].Vaccines (Basel),2022,11(1):1.

Van den Steen P, Cheuvart B, Deraedt Q, et al. Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases[J]. Hum Vaccin Immunother, 2023,19(1):2159731.

Kandeil W, Atanasov P, Avramioti D, et al. The burden of pertussis in older adults:what is the role of vaccination?A systematic literature review[J].Expert Rev Vaccines, 2019,18(5):439-455.

Aris E, Harrington L, Bhavsar A, et al. Burden of pertussis in COPD:a retrospective database study in England[J]. COPD, 2021,18:157-169.

Buck PO, Meyers JL, Gordon LD, et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims[J]. Epidemiol Infect, 2017,145(10):2109-2121.

Feredj E, Wiedemann A, Krief C, et al. Immune response to pertussis vaccine in COPD patients[J]. Sci Rep, 2023,13(1):11654.

王璐瑶,张秀峰,王慧虹,等.慢性阻塞性肺疾病患者百白破疫苗接种意愿的影响因素分析[J].海南医学,2022,33(12):1574-1577.

Flacco ME, Acuti Martellucci C, Soldato G, et al. Predictors of SARS-CoV-2 infection and severe and lethal COVID-19 after three years of follow-Up: a population-wide study[J]. Viruses, 2023,15(9):1794.

Higham A, Mathioudakis A, Vestbo J, et al. COVID-19 and COPD:a narrative review of the basic science and clinical outcomes[J]. Eur Respir Rev, 2020,29(158):200199.

Polverino F, Kheradmand F. COVID-19,COPD,and AECOPD:immunological, epidemiological, and clinical aspects[J]. Front Med

(Lausanne), 2021,7:627278.

Leung JM, Niikura M, Yang CWT, et al. COVID-19 and COPD[J]. Eur Respir J, 2020,56(2):2002108.

冯惠.慢阻肺与新冠肺炎患者不良结局相关性的荟萃分析[D].太原:山西医科大学,2023.

Meza D, Khuder B, Bailey JI, et al. Mortality from COVID-19 in patients with COPD:a US study in the N3C data enclave[J]. Int J Chron Obstruct Pulmon Dis, 2021,16:2323-2326.

陈盼,杨剑,肖永红.新型冠状病毒疫苗的研究进展[J/OL].医药导报:1-18[2023-10-24].http://kns.cnki.net/kcms/detail/42.1293.R.20230927.1046.002.html.

Kwok WC, Leung SHI, Tam TCC, et al.Efficacy of mRNA and inactivated whole virus vaccines against COVID-19 in patients with chronic respiratory diseases[J]. Int J Chron Obstruct Pulmon Dis, 2023,18:47-56.

Southworth T, Jackson N, Singh D. Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects[J]. Eur Respir J, 2022,60(2):2200497.

Lv G, Yuan J, Xiong X, et al. Mortality rate and characteristics of deaths following COVID-19 vaccination[J]. Front Med (Lausanne), 2021,8:670370.

Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern:a narrative review[J]. Clin Microbiol Infect, 2022,28(2):202-221.

特殊健康状况成人新型冠状病毒疫苗接种专家建议编写组.特殊健康状况成人新型冠状病毒疫苗接种专家建议[J].上海医学,2023,46(6):345-358.

Hu W, Fang L, Zhang H, et al. Global disease burden of COPD from 1990 to 2019 and prediction of future disease burden trend in China[J]. Public Health, 2022,208:89-97.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i1.15590